Conduit Pharmaceuticals Inc. – NASDAQ:CDT

Add to watchlist

$1.53

+1.46

+2445.59%

Market closed

Open in 2 days

-77.14%

month

-77.14%

quarter

-98.85%

year

Market Cap	6.59M
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	-0.39

Revenue	N/A
EBITDA	-530K
Income	-2.31M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Conduit Pharmaceuticals Inc. (NASDAQ:CDT): Profit margin
Jun 2023	0	-2.50M
Sep 2023	0	1.98M
Dec 2023	0	1.77M
Mar 2024	535.67M	-3.57M	-0.67%

Conduit Pharmaceuticals Inc. (NASDAQ:CDT): Debt to assets
Jun 2023	5000	15.41M	308260%
Sep 2023	12018000	13.09M	108.99%
Dec 2023	7224000	7.68M	106.33%
Mar 2024	4917000	8.01M	163.03%

Conduit Pharmaceuticals Inc. (NASDAQ:CDT): Cash Flow
Jun 2023	-429K	404K	11K
Sep 2023	-1.78M	-114.24M	124.74M
Dec 2023	-4.80M	497K	-414K
Mar 2024	-2.35M	-24.19M	-64.93M

Conduit Pharmaceuticals alternative data

Conduit Pharmaceuticals
Employees

Conduit Pharmaceuticals Inc. (NASDAQ:CDT): Employee count
Mar 2024	3
Apr 2024	3
May 2024	7
Jun 2024	7
Jul 2024	7

Conduit Pharmaceuticals
Insider Trading

Conduit Pharmaceuticals Inc. (NASDAQ:CDT): Insider trades (number of shares)
Period	Buy	Sel
Apr 2024	200332	200332
Jul 2024	0	15301068
Sep 2024	0	1016823
Oct 2024	0	5391177

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	7 Oct 2024	NIRLAND LTD 10 percent owner 10 percent owner	Common Stock, par value $0.0001 per share	939,009	$0.1	$96,718
Sale	4 Oct 2024	NIRLAND LTD 10 percent owner 10 percent owner	Common Stock, par value $0.0001 per share	1,368,991	$0.1	$141,006
Sale	3 Oct 2024	NIRLAND LTD 10 percent owner 10 percent owner	Common Stock, par value $0.0001 per share	1,500,000	$0.1	$156,000
Sale	2 Oct 2024	NIRLAND LTD 10 percent owner 10 percent owner	Common Stock, par value $0.0001 per share	333,177	$0.1	$34,317
Sale	1 Oct 2024	NIRLAND LTD 10 percent owner 10 percent owner	Common Stock, par value $0.0001 per share	1,250,000	$0.11	$141,250
Sale	30 Sep 2024	NIRLAND LTD 10 percent owner 10 percent owner	Common Stock, par value $0.0001 per share	1,016,823	$0.12	$122,019
Sale	17 Jul 2024	REGAN ANDREW director, 10 percent owner: director, 10 percent owner:	Common Stock	1,514,100	$0.26	$390,638
Sale	16 Jul 2024	REGAN ANDREW director, 10 percent owner: director, 10 percent owner:	Common Stock	10,244,392	$0.32	$3,247,472
Sale	15 Jul 2024	REGAN ANDREW director, 10 percent owner: director, 10 percent owner:	Common Stock	1,005,200	$0.25	$248,284
Sale	12 Jul 2024	REGAN ANDREW director, 10 percent owner: director, 10 percent owner:	Common Stock	1,389,820	$0.25	$343,286

CDT insider trading transactions

Conduit Pharmaceuticals
Latest News

Friday, 27 December 2024
08:30	CDT Environmental Technology Reports 2024 Unaudited Interim Financial Results and Provides Business Updates	globenewswire.com
Thursday, 12 December 2024
07:30	Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics	globenewswire.com
Thursday, 21 November 2024
07:30	Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders	globenewswire.com
Tuesday, 19 November 2024
16:30	Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors	globenewswire.com
Monday, 4 November 2024
07:30	Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline	globenewswire.com
Friday, 1 November 2024
16:45	Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes	globenewswire.com
Wednesday, 14 August 2024
11:41	Why Is Conduit Pharmaceuticals (CDT) Stock Up 12% Today?	investorplace.com
Monday, 12 August 2024
07:00	Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders	globenewswire.com
Thursday, 8 August 2024
08:37	4 Stocks Moving Sharply Before the Market Opens	247wallst.com
07:57	Why Is Conduit Pharmaceuticals (CDT) Stock Up 123% Today?	investorplace.com
06:30	Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments	globenewswire.com
Tuesday, 16 July 2024
08:12	Why Is Conduit Pharmaceuticals (CDT) Stock Up 73% Today?	investorplace.com
Thursday, 27 June 2024
08:00	CDT Environmental Technology Investment Holdings Limited Announces Strategic Partnership with Leading Pipeline Inspection and Data Services Provider in Fujian	globenewswire.com
Tuesday, 18 June 2024
08:30	CDT Environmental Technology Investment Holdings Limited Announces Strategic Cooperation Agreement with Subsidiary of Chinese State-Owned Construction Group	globenewswire.com
Wednesday, 22 May 2024
08:01	CDT Environmental Technology Investment Holdings Limited Establishes Partnership with Fortune 500 Company's Subsidiary to Jointly Bid for Large-Scale Sewage Treatment Facility in Hengqin, China	globenewswire.com
07:00	AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024	businesswire.com
Monday, 20 May 2024
20:00	CDT Environmental Technology Investment Holdings Limited Files Annual Report on Form 20-F	globenewswire.com
Tuesday, 2 April 2024
17:53	Will There Be a TikTok Ban? When, Why and What You Should Know.	InvestorPlace
Wednesday, 31 January 2024
08:30	Conduit Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	GlobeNewsWire

Frequently Asked Questions (FAQ)

What's the price of Conduit Pharmaceuticals stock today?

One share of Conduit Pharmaceuticals stock can currently be purchased for approximately $1.53.
When is Conduit Pharmaceuticals's next earnings date?

Unfortunately, Conduit Pharmaceuticals's (CDT) next earnings date is currently unknown.
Does Conduit Pharmaceuticals pay dividends?

No, Conduit Pharmaceuticals does not pay dividends.
How much money does Conduit Pharmaceuticals make?

Conduit Pharmaceuticals has a market capitalization of 6.59M.
What is Conduit Pharmaceuticals's stock symbol?

Conduit Pharmaceuticals Inc. is traded on the NASDAQ under the ticker symbol "CDT".
What is Conduit Pharmaceuticals's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Conduit Pharmaceuticals?

Shares of Conduit Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does Conduit Pharmaceuticals have?

As Jul 2024, Conduit Pharmaceuticals employs 7 workers, which is 133% more then previous quarter.
When Conduit Pharmaceuticals went public?

Conduit Pharmaceuticals Inc. is publicly traded company for more then 3 years since IPO on 28 Mar 2022.
What is Conduit Pharmaceuticals's official website?

The official website for Conduit Pharmaceuticals is conduitpharma.com.
Where are Conduit Pharmaceuticals's headquarters?

Conduit Pharmaceuticals is headquartered at 4995 Murphy Canyon Road, San Diego, CA.
How can i contact Conduit Pharmaceuticals?

Conduit Pharmaceuticals's mailing address is 4995 Murphy Canyon Road, San Diego, CA and company can be reached via phone at +7 604718536.

Conduit Pharmaceuticals Inc.

conduitpharma.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Conduit Pharmaceuticals Inc. operates as a clinical stage specialty biopharmaceutical company that provides unmet medical needs in the areas of autoimmune disease and idiopathic male infertility. It's pipeline includes AZD1656 for the treatment of hashimoto's thyroiditis, renal transplant, uveitis, and preterm labor; and AZD5904 for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

+7 604718536

4995 Murphy Canyon Road
San Diego, CA 92134

CIK: 0001896212
ISIN: US20678X1063
CUSIP: 20678X106